{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:08:25Z","timestamp":1795118905428,"version":"4.10.3"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","award":["A2019446S"],"award-info":[{"award-number":["A2019446S"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021594","name":"Demensfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009244","name":"Stockholm University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009244","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Low levels of plasma apolipoprotein E (apoE) and presence of the\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 allele are associated with an increased risk of Alzheimer\u2019s disease (AD). Although the increased risk of AD in\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54-carriers is well-established, the protein levels have received limited attention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We here report the total plasma apoE and apoE isoform levels at baseline from a longitudinally (24\u00a0months) followed cohort including controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939), patients with stable amnestic mild cognitive impairment during 24\u00a0months follow up (MCI-MCI,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930), patients with amnestic MCI (aMCI) that during follow-up were clinically diagnosed with AD with dementia (ADD) (MCI-ADD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928), and patients with AD with dementia (ADD) at baseline (ADD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928). We furthermore assessed associations between plasma apoE levels with cerebrospinal fluid (CSF) AD biomarkers and \u03b1-synuclein, as well as both CSF and plasma neurofilament light chain (NfL), YKL-40 and kallikrein 6.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Irrespective of clinical diagnosis, the highest versus the lowest apoE levels were found in\n                      <jats:italic>APOE\u00a0<\/jats:italic>\n                      \u03b52\/\u03b53 versus\n                      <jats:italic>APOE\u00a0<\/jats:italic>\n                      \u03b54\/\u03b54 subjects, with the most prominent differences exhibited in females. Total plasma apoE levels were 32% and 21% higher in the controls versus MCI-ADD and ADD patients, respectively. Interestingly, MCI-ADD patients exhibited a 30% reduction in plasma apoE compared to MCI-MCI patients. This decrease appeared to be associated with brain amyloid-\u03b2 (A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ) pathology regardless of disease status as assessed using the Amyloid, Tau, and Neurodegeneration (A\/T\/N) classification. In addition to the association between low plasma apoE and low levels of CSF A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      , lower apoE levels were also related to higher levels of CSF total tau (t-tau) and tau phosphorylated at Threonine 181 residue (p-tau) and NfL as well as a worse performance on the mini-mental-state-examination. In MCI-ADD patients, low levels of plasma apoE were associated with higher levels of CSF \u03b1-synuclein and kallikrein 6. No significant correlations between plasma apoE and the astrocytic inflammatory marker YKL40 were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrate important associations between low plasma apoE levels, A\u03b2 pathology, and progression from aMCI to a clinical ADD diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-01058-9","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T04:04:17Z","timestamp":1661313857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Andreas","family":"Giannisis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Al-Grety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalicharan","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Twohig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid Botne","family":"Sando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril Rolfseng","family":"Gr\u00f8ntvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Br\u00e5then","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kultima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrietta M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"issue":"8","key":"1058_CR1","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1016\/S0021-9258(18)34702-1","volume":"257","author":"SC Rall Jr","year":"1982","unstructured":"Rall SC Jr, Weisgraber KH, Mahley RW, Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982;257(8):4171\u20138.","journal-title":"J Biol Chem."},{"issue":"17","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"9077","DOI":"10.1016\/S0021-9258(19)52510-8","volume":"256","author":"KH Weisgraber","year":"1981","unstructured":"Weisgraber KH, Rall SC Jr, Mahley RW, Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981;256(17):9077\u201383.","journal-title":"J Biol Chem."},{"issue":"8","key":"1058_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tibs.2006.06.008","volume":"31","author":"DM Hatters","year":"2006","unstructured":"Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31(8):445\u201354.","journal-title":"Trends Biochem Sci"},{"issue":"4852","key":"1058_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.3283935","volume":"240","author":"RW Mahley","year":"1988","unstructured":"Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622\u201330.","journal-title":"Science"},{"issue":"1","key":"1058_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1172\/JCI115288","volume":"88","author":"MF Linton","year":"1991","unstructured":"Linton MF, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991;88(1):270\u201381.","journal-title":"J Clin Invest"},{"issue":"1","key":"1058_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0304-3940(96)12716-6","volume":"211","author":"M Nakai","year":"1996","unstructured":"Nakai M, et al. Expression of apolipoprotein E mRNA in rat microglia. Neurosci Lett. 1996;211(1):41\u20134.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1058_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/glia.440020306","volume":"2","author":"G Stoll","year":"1989","unstructured":"Stoll G, et al. Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve. Glia. 1989;2(3):170\u20136.","journal-title":"Glia"},{"issue":"12","key":"1058_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18(12):759\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1058_CR9","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1084\/jem.20190980","volume":"216","author":"Y Shi","year":"2019","unstructured":"Shi Y, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546\u201361.","journal-title":"J Exp Med"},{"issue":"3","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566-581 e9.","journal-title":"Immunity"},{"issue":"4","key":"1058_CR11","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1172\/JCI112130","volume":"76","author":"JK Boyles","year":"1985","unstructured":"Boyles JK, et al. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76(4):1501\u201313.","journal-title":"J Clin Invest"},{"issue":"14","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1523\/JNEUROSCI.4213-04.2005","volume":"25","author":"MM Wilhelmus","year":"2005","unstructured":"Wilhelmus MM, et al. Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. J Neurosci. 2005;25(14):3621\u20137.","journal-title":"J Neurosci"},{"issue":"5","key":"1058_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.neuron.2012.11.020","volume":"76","author":"RW Mahley","year":"2012","unstructured":"Mahley RW, Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron. 2012;76(5):871\u201385.","journal-title":"Neuron"},{"issue":"9","key":"1058_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/iub.1314","volume":"66","author":"MC Phillips","year":"2014","unstructured":"Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66(9):616\u201323.","journal-title":"IUBMB Life"},{"issue":"11","key":"1058_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/jnnp-2013-307228","volume":"85","author":"G Berge","year":"2014","unstructured":"Berge G, et al. Apolipoprotein E epsilon2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry. 2014;85(11):1227\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8873","key":"1058_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","volume":"342","author":"J Poirier","year":"1993","unstructured":"Poirier J, et al. Apolipoprotein E polymorphism and Alzheimer\u2019s disease. Lancet. 1993;342(8873):697\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1058_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180\u20134.","journal-title":"Nat Genet"},{"issue":"5","key":"1058_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward. Neuron. 2019;101(5):820\u201338.","journal-title":"Neuron"},{"issue":"20","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1093\/hmg\/dds296","volume":"21","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer\u2019s disease. Hum Mol Genet. 2012;21(20):4558\u201371.","journal-title":"Hum Mol Genet"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.euprot.2015.07.012","volume":"8","author":"M Rezeli","year":"2015","unstructured":"Rezeli M, et al. Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer\u2019s disease and other neurodegenerative diseases. EuPA Open Proteom. 2015;8:137\u201343.","journal-title":"EuPA Open Proteom"},{"issue":"5","key":"1058_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients and controls. Acta Neuropathol. 2014;127(5):633\u201343.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1058_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089041","volume":"9","author":"C Wang","year":"2014","unstructured":"Wang C, et al. Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer\u2019s disease. PLoS ONE. 2014;9(2): e89041.","journal-title":"PLoS ONE"},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neulet.2016.02.018","volume":"617","author":"FJ Wolters","year":"2016","unstructured":"Wolters FJ, et al. Serum apolipoprotein E is associated with long-term risk of Alzheimer\u2019s disease: the Rotterdam Study. Neurosci Lett. 2016;617:139\u201342.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1058_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jalz.2017.05.006","volume":"14","author":"KL Rasmussen","year":"2018","unstructured":"Rasmussen KL, et al. Plasma apolipoprotein E levels and risk of dementia: A Mendelian randomization study of 106,562 individuals. Alzheimers Dement. 2018;14(1):71\u201380.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1058_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0304-3940(97)13394-8","volume":"223","author":"K Taddei","year":"1997","unstructured":"Taddei K, et al. Increased plasma apolipoprotein E (apoE) levels in Alzheimer\u2019s disease. Neurosci Lett. 1997;223(1):29\u201332.","journal-title":"Neurosci Lett"},{"issue":"53","key":"1058_CR26","doi-asserted-by":"publisher","first-page":"27204","DOI":"10.1074\/jbc.M116.721779","volume":"291","author":"AT Baker-Nigh","year":"2016","unstructured":"Baker-Nigh AT, et al. Human central nervous system (CNS) ApoE isoforms are increased by age, differentially altered by amyloidosis, and relative amounts reversed in the CNS compared with plasma. J Biol Chem. 2016;291(53):27204\u201318.","journal-title":"J Biol Chem"},{"issue":"1","key":"1058_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-020-00585-7","volume":"12","author":"K Minta","year":"2020","unstructured":"Minta K, et al. Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimers Res Ther. 2020;12(1):19.","journal-title":"Alzheimers Res Ther"},{"key":"1058_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1750-1326-2-7","volume":"2","author":"SE Wahrle","year":"2007","unstructured":"Wahrle SE, et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007;2:7.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"1058_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1023\/A:1007516210548","volume":"25","author":"C Hesse","year":"2000","unstructured":"Hesse C, et al. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res. 2000;25(4):511\u20137.","journal-title":"Neurochem Res"},{"issue":"2","key":"1058_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0304-3940(97)00429-1","volume":"229","author":"M Lindh","year":"1997","unstructured":"Lindh M, et al. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer\u2019s disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett. 1997;229(2):85\u20138.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1058_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0022-510X(96)00234-1","volume":"145","author":"A Merched","year":"1997","unstructured":"Merched A, et al. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer\u2019s disease. J Neurol Sci. 1997;145(1):33\u20139.","journal-title":"J Neurol Sci"},{"issue":"3\u20134","key":"1058_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000368982","volume":"39","author":"E Teng","year":"2015","unstructured":"Teng E, et al. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer\u2019s disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord. 2015;39(3\u20134):154\u201366.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1196\/annals.1395.013","volume":"1100","author":"SP Mooijaart","year":"2007","unstructured":"Mooijaart SP, et al. Plasma levels of apolipoprotein E and cognitive function in old age. Ann N Y Acad Sci. 2007;1100:148\u201361.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1058_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ana.24326","volume":"77","author":"KL Rasmussen","year":"2015","unstructured":"Rasmussen KL, et al. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol. 2015;77(2):301\u201311.","journal-title":"Ann Neurol"},{"issue":"6","key":"1058_CR35","doi-asserted-by":"publisher","first-page":"e38013","DOI":"10.1371\/journal.pone.0038013","volume":"7","author":"KR Wildsmith","year":"2012","unstructured":"Wildsmith KR, et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One. 2012;7(6):e38013.","journal-title":"PLoS One"},{"issue":"9","key":"1058_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"issue":"1","key":"1058_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-016-0231-9","volume":"9","author":"HM Nielsen","year":"2017","unstructured":"Nielsen HM, et al. Peripheral apoE isoform levels in cognitively normal APOE epsilon3\/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther. 2017;9(1):5.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1058_CR38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1021\/pr401060x","volume":"13","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, et al. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J Proteome Res. 2014;13(2):1077\u201387.","journal-title":"J Proteome Res"},{"issue":"4","key":"1058_CR39","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3233\/JAD-190175","volume":"71","author":"K Patra","year":"2019","unstructured":"Patra K, et al. Plasma apolipoprotein E monomer and dimer profile and relevance to Alzheimer\u2019s disease. J Alzheimers Dis. 2019;71(4):1217\u201331.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1058_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3233\/JAD-191227","volume":"74","author":"GR Grontvedt","year":"2020","unstructured":"Grontvedt GR, et al. The Amyloid, Tau, and Neurodegeneration (A\/T\/N) classification applied to a clinical research cohort with long-term follow-up. J Alzheimers Dis. 2020;74(3):829\u201337.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1058_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, et al. Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240\u20136.","journal-title":"J Intern Med"},{"issue":"7","key":"1058_CR42","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"issue":"1","key":"1058_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12883-016-0706-0","volume":"16","author":"G Berge","year":"2016","unstructured":"Berge G, et al. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer\u2019s disease, mild cognitive impairment, or healthy controls: a two year follow-up study. BMC Neurol. 2016;16(1):180.","journal-title":"BMC Neurol"},{"issue":"1","key":"1058_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-018-0336-4","volume":"10","author":"K Patra","year":"2018","unstructured":"Patra K, et al. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):9.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1058_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40478-018-0624-z","volume":"6","author":"D Twohig","year":"2018","unstructured":"Twohig D, et al. The relevance of cerebrospinal fluid alpha-synuclein levels to sporadic and familial Alzheimer\u2019s disease. Acta Neuropathol Commun. 2018;6(1):130.","journal-title":"Acta Neuropathol Commun"},{"key":"1058_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fnagi.2017.00210","volume":"9","author":"C Lauridsen","year":"2017","unstructured":"Lauridsen C, et al. Cerebrospinal fluid Abeta43 is reduced in early-onset compared to late-onset Alzheimer\u2019s disease, but has similar diagnostic accuracy to Abeta42. Front Aging Neurosci. 2017;9:210.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"1058_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JAD-150234","volume":"49","author":"G Berge","year":"2016","unstructured":"Berge G, et al. Effect of Tween-20 on core biomarkers measured in cerebrospinal fluid from patients with Alzheimer\u2019s disease, mild cognitive impairment, or healthy control individuals. J Alzheimers Dis. 2016;49(2):493\u2013502.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"1058_CR48","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.jalz.2018.04.008","volume":"14","author":"RA Nebel","year":"2018","unstructured":"Nebel RA, et al. Understanding the impact of sex and gender in Alzheimer\u2019s disease: a call to action. Alzheimers Dement. 2018;14(9):1171\u201383.","journal-title":"Alzheimers Dement"},{"key":"1058_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","volume":"160","author":"BC Riedel","year":"2016","unstructured":"Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of Alzheimer\u2019s disease. J Steroid Biochem Mol Biol. 2016;160:134\u201347.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"1058_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology"},{"issue":"12","key":"1058_CR51","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.3390\/jcm9123995","volume":"9","author":"A Buczynska","year":"2020","unstructured":"Buczynska A, et al. The significance of apolipoprotein E measurement in the screening of fetal down syndrome. J Clin Med. 2020;9(12):3995.","journal-title":"J Clin Med"},{"key":"1058_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/JAA.S211569","volume":"12","author":"M Bhowmik","year":"2019","unstructured":"Bhowmik M, et al. Pilot-scale study of human plasma proteomics identifies ApoE And IL33 as markers in atopic asthma. J Asthma Allergy. 2019;12:273\u201383.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"1058_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.aohep.2019.07.011","volume":"19","author":"JCR Nascimento","year":"2020","unstructured":"Nascimento JCR, et al. Impact of apolipoprotein E genetic polymorphisms on liver disease: an essential review. Ann Hepatol. 2020;19(1):24\u201330.","journal-title":"Ann Hepatol"},{"key":"1058_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jad.2015.09.024","volume":"190","author":"P Asellus","year":"2016","unstructured":"Asellus P, et al. Plasma apolipoprotein E and severity of suicidal behaviour. J Affect Disord. 2016;190:137\u201342.","journal-title":"J Affect Disord"},{"issue":"10","key":"1058_CR55","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1212\/WNL.44.10.1950","volume":"44","author":"D Galasko","year":"1994","unstructured":"Galasko D, et al. The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer\u2019s disease. Neurology. 1994;44(10):1950\u20131.","journal-title":"Neurology"},{"issue":"2","key":"1058_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang D, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223\u20138.","journal-title":"JAMA Neurol"},{"issue":"30","key":"1058_CR57","doi-asserted-by":"publisher","first-page":"15226","DOI":"10.1073\/pnas.1821409116","volume":"116","author":"W Paslawski","year":"2019","unstructured":"Paslawski W, et al. Alpha-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson\u2019s disease patients. Proc Natl Acad Sci U S A. 2019;116(30):15226\u201335.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1058_CR58","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/jmedgenet-2012-101175","volume":"49","author":"CM Lill","year":"2012","unstructured":"Lill CM, et al. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet. 2012;49(9):558\u201362.","journal-title":"J Med Genet"},{"issue":"7\u20138","key":"1058_CR59","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3109\/21678421.2014.918149","volume":"15","author":"F Govone","year":"2014","unstructured":"Govone F, et al. Lack of association between APOE gene polymorphisms and amyotrophic lateral sclerosis: a comprehensive meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7\u20138):551\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"1058_CR60","first-page":"46","volume":"18","author":"BB Gelman","year":"1988","unstructured":"Gelman BB, et al. Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis. Ann Clin Lab Sci. 1988;18(1):46\u201352.","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"1058_CR61","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1212\/WNL.58.7.1112","volume":"58","author":"L Lacomblez","year":"2002","unstructured":"Lacomblez L, et al. APOE: a potential marker of disease progression in ALS. Neurology. 2002;58(7):1112\u20134.","journal-title":"Neurology"},{"issue":"4","key":"1058_CR62","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00001756-200303240-00016","volume":"14","author":"F Panza","year":"2003","unstructured":"Panza F, et al. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer\u2019s disease patients and centenarians. NeuroReport. 2003;14(4):605\u20138.","journal-title":"NeuroReport"},{"issue":"2","key":"1058_CR63","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5114\/fn.2019.84828","volume":"57","author":"M Prendecki","year":"2019","unstructured":"Prendecki M, et al. APOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer\u2019s disease. Folia Neuropathol. 2019;57(2):106\u201316.","journal-title":"Folia Neuropathol"},{"issue":"1","key":"1058_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0014-4886(03)00088-8","volume":"183","author":"H Fukumoto","year":"2003","unstructured":"Fukumoto H, et al. APOE epsilon 3\/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer\u2019s disease diagnosis. Exp Neurol. 2003;183(1):249\u201353.","journal-title":"Exp Neurol"},{"issue":"12","key":"1058_CR65","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1093\/hmg\/6.12.2151","volume":"6","author":"JC Lambert","year":"1997","unstructured":"Lambert JC, et al. Distortion of allelic expression of apolipoprotein E in Alzheimer\u2019s disease. Hum Mol Genet. 1997;6(12):2151\u20134.","journal-title":"Hum Mol Genet"},{"issue":"22","key":"1058_CR66","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1093\/hmg\/ddh299","volume":"13","author":"NJ Bray","year":"2004","unstructured":"Bray NJ, et al. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum Mol Genet. 2004;13(22):2885\u201392.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"1058_CR67","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI113243","volume":"80","author":"MS Weintraub","year":"1987","unstructured":"Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest. 1987;80(6):1571\u20137.","journal-title":"J Clin Invest"},{"issue":"3","key":"1058_CR68","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1172\/JCI112645","volume":"78","author":"RE Gregg","year":"1986","unstructured":"Gregg RE, et al. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986;78(3):815\u201321.","journal-title":"J Clin Invest"},{"issue":"1","key":"1058_CR69","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ab.2009.07.049","volume":"395","author":"KR Wildsmith","year":"2009","unstructured":"Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Anal Biochem. 2009;395(1):116\u20138.","journal-title":"Anal Biochem"},{"issue":"45","key":"1058_CR70","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","volume":"28","author":"DR Riddell","year":"2008","unstructured":"Riddell DR, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28(45):11445\u201353.","journal-title":"J Neurosci"},{"key":"1058_CR71","doi-asserted-by":"publisher","unstructured":"Giannisis A, et al. Brain integrity is altered by hepatic APOE epsilon4 in humanized-liver mice. Mol Psychiatry. 2022. https:\/\/doi.org\/10.1038\/s41380-022-01548-0.","DOI":"10.1038\/s41380-022-01548-0"},{"issue":"12","key":"1058_CR72","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/nu14122474","volume":"14","author":"I BegcevicBrkovic","year":"2022","unstructured":"BegcevicBrkovic I, et al. Simultaneous mass spectrometry-based apolipoprotein profiling and apolipoprotein E phenotyping in patients with ASCVD and mild cognitive impairment. Nutrients. 2022;14(12):2474.","journal-title":"Nutrients"},{"issue":"2","key":"1058_CR73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000330492","volume":"32","author":"J Norberg","year":"2011","unstructured":"Norberg J, et al. Regional differences in effects of APOE \u03b54 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord. 2011;32(2):135\u201342.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"1058_CR74","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archneur.62.12.noc50161","volume":"62","author":"MC Morris","year":"2005","unstructured":"Morris MC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol. 2005;62(12):1849\u201353.","journal-title":"Arch Neurol"},{"issue":"2","key":"1058_CR75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3945\/ajcn.115.124081","volume":"103","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, et al. Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr. 2016;103(2):330\u201340.","journal-title":"Am J Clin Nutr"},{"key":"1058_CR76","doi-asserted-by":"publisher","unstructured":"Harriden B, et al. Are dietary patterns becoming more processed? The effects of different dietary patterns on cognition: A review. Nutr Health. 2022;28(3):341\u201356. https:\/\/doi.org\/10.1177\/02601060221094129.","DOI":"10.1177\/02601060221094129"},{"issue":"9984","key":"1058_CR77","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255\u201363.","journal-title":"Lancet"},{"issue":"2","key":"1058_CR78","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/nu10020229","volume":"10","author":"B Shakersain","year":"2018","unstructured":"Shakersain B, et al. The Nordic prudent diet reduces risk of cognitive decline in the swedish older adults: a population-based cohort study. Nutrients. 2018;10(2):229.","journal-title":"Nutrients"},{"issue":"4","key":"1058_CR79","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaneurol.2017.4365","volume":"75","author":"A Solomon","year":"2018","unstructured":"Solomon A, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75(4):462\u201370.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1058_CR80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122\u201331.","journal-title":"Ann Neurol"},{"issue":"5 Suppl","key":"1058_CR81","first-page":"S290","volume":"10","author":"S Slaets","year":"2014","unstructured":"Slaets S, et al. Increased CSF alpha-synuclein levels in Alzheimer\u2019s disease: correlation with tau levels. Alzheimers Dement. 2014;10(5 Suppl):S290\u20138.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1058_CR82","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68(10):903\u201312.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"1058_CR83","doi-asserted-by":"publisher","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","volume":"10","author":"M Wennstrom","year":"2015","unstructured":"Wennstrom M, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer\u2019s but not Parkinson\u2019s disease or dementia with Lewy bodies. PLoS One. 2015;10(8):e0135458.","journal-title":"PLoS One"},{"issue":"1","key":"1058_CR84","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1058_CR85","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"D Twohig","year":"2019","unstructured":"Twohig D, Nielsen HM. alpha-synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):23.","journal-title":"Mol Neurodegener"},{"issue":"529","key":"1058_CR86","doi-asserted-by":"publisher","first-page":"eaay3069","DOI":"10.1126\/scitranslmed.aay3069","volume":"12","author":"A Davis Albert","year":"2020","unstructured":"Davis Albert A, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Trans Medi. 2020;12(529):eaay3069.","journal-title":"Sci Trans Medi"},{"issue":"529","key":"1058_CR87","doi-asserted-by":"publisher","first-page":"eaay1809","DOI":"10.1126\/scitranslmed.aay1809","volume":"12","author":"N Zhao","year":"2020","unstructured":"Zhao N, et al. APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12(529):eaay1809.","journal-title":"Sci Transl Med"},{"key":"1058_CR88","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3233\/JAD-130458","volume":"36","author":"A Korff","year":"2013","unstructured":"Korff A, et al. \u03b1-Synuclein in cerebrospinal fluid of Alzheimer\u2019s disease and mild cognitive impairment. J Alzheimers Dis. 2013;36:679\u201388.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1058_CR89","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","volume":"81","author":"K Kasuga","year":"2010","unstructured":"Kasuga K, et al. Differential levels of \u03b1-synuclein, \u03b2-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2010;81(6):608.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1058_CR90","doi-asserted-by":"publisher","first-page":"e81654","DOI":"10.1371\/journal.pone.0081654","volume":"8","author":"E Kapaki","year":"2013","unstructured":"Kapaki E, et al. The diagnostic value of CSF \u03b1-Synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer\u2019s disease. PLOS One. 2013;8(11):e81654.","journal-title":"PLOS One"},{"issue":"1","key":"1058_CR91","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JAD-2012-111655","volume":"29","author":"M Wennstrom","year":"2012","unstructured":"Wennstrom M, et al. Altered CSF orexin and alpha-synuclein levels in dementia patients. J Alzheimers Dis. 2012;29(1):125\u201332.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1058_CR92","doi-asserted-by":"publisher","first-page":"e53250","DOI":"10.1371\/journal.pone.0053250","volume":"8","author":"M Wennstrom","year":"2013","unstructured":"Wennstrom M, et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One. 2013;8(1):e53250.","journal-title":"PLoS One"},{"issue":"5","key":"1058_CR93","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1058_CR94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60\u20137.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1058_CR95","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-018-0339-1","volume":"10","author":"L Gaetani","year":"2018","unstructured":"Gaetani L, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10(1):8.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1058_CR96","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0022-2275(20)37876-7","volume":"24","author":"NR Phillips","year":"1983","unstructured":"Phillips NR, Havel RJ, Kane JP. Sex-related differences in the concentrations of apolipoprotein E in human blood plasma and plasma lipoproteins. J Lipid Res. 1983;24(11):1525\u201331.","journal-title":"J Lipid Res"},{"issue":"2","key":"1058_CR97","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0009-8981(87)90024-6","volume":"163","author":"N Rifai","year":"1987","unstructured":"Rifai N, Silverman LM. A simple immunotechnique for the determination of serum concentration of apolipoprotein E. Clin Chim Acta. 1987;163(2):207\u201313.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"1058_CR98","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/clinchem\/44.5.957","volume":"44","author":"M Vincent-Viry","year":"1998","unstructured":"Vincent-Viry M, et al. Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clin Chem. 1998;44(5):957\u201365.","journal-title":"Clin Chem"},{"issue":"Suppl 2","key":"1058_CR99","doi-asserted-by":"publisher","first-page":"S527","DOI":"10.3233\/JAD-2010-100501","volume":"20","author":"J Vina","year":"2010","unstructured":"Vina J, Lloret A. Why women have more Alzheimer\u2019s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis. 2010;20(Suppl 2):S527\u201333.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1058_CR100","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11682-013-9272-x","volume":"8","author":"L Ungar","year":"2014","unstructured":"Ungar L, Altmann A, Greicius MD. Apolipoprotein E, gender, and Alzheimer\u2019s disease: an overlooked, but potent and promising interaction. Brain Imaging Behav. 2014;8(2):262\u201373.","journal-title":"Brain Imaging Behav"},{"key":"1058_CR101","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/JAD-210065","volume":"81","author":"AK Edlund","year":"2021","unstructured":"Edlund AK, et al. Plasma apolipoprotein E3 and glucose levels are associated in APOE \u025b3\/\u025b4 carriers. J Alzheimers Dis. 2021;81:339\u201354.","journal-title":"J Alzheimers Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01058-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T04:08:46Z","timestamp":1661314126000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01058-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional ethics committees in Trondheim, Norway (2010\/226) and Stockholm (2016\/771\u201331\/4), Sweden, and carried out in agreement with the Helsinki Declaration. Written informed consent was obtained from all studied individuals or suitable proxies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}